Zaid Rana
Gastroenterology · Miami, FLNPI 1558801159
Payments from drug & device makers
Across 1,062 payments — averaging $5073.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$3.1M
- Teva Pharmaceuticals USA, Inc.$1.1M
- Takeda Pharmaceuticals U.S.A., Inc.$454K
- Incyte Corporation$424K
- Chiesi USA, Inc.$168K
- Boehringer Ingelheim International GmbH$149K
- plus $23K from 16 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 74 | $3,056,670 |
| Teva Pharmaceuticals USA, Inc. | 57 | $1,113,228 |
| Takeda Pharmaceuticals U.S.A., Inc. | 398 | $454,471 |
| Incyte Corporation | 368 | $424,075 |
| Chiesi USA, Inc. | 28 | $167,875 |
| Boehringer Ingelheim International GmbH | 71 | $149,159 |
| Astrazeneca UK Limited | 1 | $18,450 |
| Boston Scientific | 22 | $3,065 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 11 | $260 |
| Redhill Biopharma Inc. | 10 | $201 |
| Madrigal Pharmaceuticals | 6 | $179 |
| Fujifilm Healthcare Americas Corporation | 2 | $140 |
| Bristol Myers Squibb | 1 | $135 |
| Janssen Scientific Affairs, LLC | 1 | $122 |
| Esperion Therapeutics, Inc. | 1 | $119 |
| Gilead | 1 | $109 |
| NS Pharma, Inc. | 1 | $53 |
| Merck | 3 | $44 |
| Intercept Pharmaceuticals, Inc. | 2 | $41 |
| AbbVie | 2 | $39 |
| Johnson & Johnson | 1 | $17 |
| EMD Serono, Inc. | 1 | $16 |
How this compares
$5,388,466 in reported general payments places this provider in the 95th percentile of 1,388 gastroenterology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other gastroenterology in Miami
- Angel VentoMiami$2.5M
- Francisco Bautista-MenaMiami$2M
- Miguel RodriguezMiami$2M
- Frances Robles-PenaMiami$1.7M
- Javier SobradoMiami$1.4M
- David KermanMiami$1.4M
- Lukasz KwapiszMiami$1.3M
- Oriana DamasMiami$903K
- David GoldbergMiami$858K
- Joanna LopezMiami$670K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.